Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02210117
Title Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC)
Recruitment Unknown status
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

clear cell renal cell carcinoma

Therapies

Nivolumab

Bevacizumab + Nivolumab

Ipilimumab + Nivolumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.